10 am (EST) / 3 pm (GMT) / 4pm (CET)
Join our upcoming webinar detailing how to develop control strategies in line with ICH M7 guidelines without expensive and time-consuming analytical testing. This webinar will show you how you can assess carryover risk for potentially mutagenic impurities (including nitrosamines) in your drug development workflow.
We were delighted to have Senior Principal Scientist Andy Teasdale presenting. Andy is the chair of AstraZeneca’s Impurity advisory Board, and has developed a wealth of knowledge over the last 30 years working in the pharmaceutical industry. He is leading AstraZeneca expert for a number of key impurity areas, including mutagenic impurities. Andy will describe the concept of purge factors and purge scoring for controlling potentially mutagenic impurities outside of the lab. His talk is titled ‘Industry perspective: Controlling potentially mutagenic impurities – Using calculations to support purge arguments under ICH M7’
Lhasa Limited Scientist, Emma Pye works as part of the Science team at Lhasa on our in silico tool for controlling potentially mutagenic impurities – ‘Mirabilis’ – for the last year. She will present ‘Purge Factors as part of M7 Assessment of mutagenic impurity risk – Using Mirabilis to assist in control strategies.’
The talks will be followed by a live Q&A where the team will be available to answer any questions. This session will last approximately 1.5 hrs (with questions).